We have developed a new helper adenovirus (Ad) based expression in mouse liver after intravenous injection of the on serotype 2, Ad2LC8cCARP, for use in the Cre/loxP sysAd2-based hdAd showed that the vector could efficiently tem (Parks et al. Proc Natl Acad Sci USA, 1996; 93: transduce the liver, and produce high levels of a foreign 13565-13570) to generate Ad vectors deleted of all protein transgene, similar to those expressed by the hdAd genercoding sequences (helper-dependent Ad vectors (hdAd) ).
Introduction
Recently, adenovirus (Ads) vectors have received considerable attention for transgene delivery to mammalian cells generally and for gene therapy in particular due to several advantages over other vector systems, including high transduction efficiency of a variety of cell types comprised of both replicating and non-replicating cells, ease of virus production, and relative safety. 1 However, data from preclinical and clinical studies have shown that Ads also have several disadvantages primarily due to the induction of both cellular and humoral immune responses to vector-derived antigens. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Because of these immune responses, administration of first-generation Ad vectors (ie deleted of early region 1 (E1) or E1/E3) has generally resulted in only transient transgene expression and poor expression following repeat vector administration. [14] [15] [16] [17] Reintroduction of the E3 region, which encodes functions involved in aiding virus escape from host immune responses, can prolong transgene expression in some animal models, [18] [19] [20] [21] [22] and is reported to decrease the formation of anti-Ad neutralizing antibodies. 21 The use of second-generation Ad vectors, which are further deleted or attenuated in E2 or E4, can lead to decreased inflammatory responses and a longer duration of transgene expression, [23] [24] [25] [26] [27] [28] [29] although not in all cases. 10, 11, 30, 31 However antibody responses against second-generation Ads were similar to those generated against first-generation vectors, 11 thus compromising the ability to readminister the vector.
The development of systems for the generation of helper-dependent Ad vectors (hdAd) which are deleted for most if not all viral coding sequences, [32] [33] [34] [35] [36] [37] [38] [39] has allowed production of hdAd which can provide long-term, highlevel transgene expression, [40] [41] [42] and which result in substantially reduced inflammatory and cellular immune responses. [41] [42] [43] However, as expected, deletion of all Ad coding sequences does not overcome the humoral immune response, and the resultant neutralizing antibodies (JL Bramson, RJP and FLG, unpublished results), impair the effectiveness of hdAd vector readministration.
In an attempt to prevent vector-directed immune responses, many groups have explored the use of transient immune blockage at the time of Ad vector administration, or the induction of tolerance to Ad. [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] These strategies have been somewhat successful, and allow repeat vector administration; however, complications and potential side-effects may make immune suppression impractical for clinical use. An alternative strategy to allow for repeat vector administration is the sequential use of different Ad serotypes. Neutralizing antibodies formed against one serotype should have no effect on subsequent delivery of a different serotype, and this approach has allowed repeat administration of firstgeneration Ad vectors.
46,59-61 However, a reduced persistence of expression has been observed after the second administration, 60 presumably due to cross-reacting cytotoxic T lymphocytes which can eliminate the transduced cells. 62 Over 40 different serotypes of human Ads have been isolated, suggesting that, in theory, Ad vectors of different serotypes could be administered many times throughout the life of a patient.
The Cre/loxP system for producing helper-dependent Ad vectors involves the use of a helper virus that contains a packaging signal flanked by loxP sites. 39 Upon infection of a 293-derived cell line that stably expresses the bacteriophage P1 Cre recombinase, 63 the packaging signal is excised from almost all the helper virus DNA, rendering it unpackageable. The helper virus DNA retains the ability to replicate and provides all of the functions required in trans for the replication and packaging of a hdAd. This system facilitates the generation of high-titer hdAd preparations with substantially reduced quantities of contaminating helper-virus. A key feature of the helper-dependent system is that the serotype of the hdAd is determined only by the helper virus. Therefore, in contrast to first-generation vectors that require the construction of a new vector to switch serotypes, a series of genetically identical hdAds of different serotypes could be generated simply by changing the serotype of the helper.
We have now constructed a helper virus based on the Ad2 serotype for use in the Cre/loxP system for the generation of Ad vectors deleted of all Ad protein coding sequences. Using this new virus and our previous helper virus that is based on Ad5, we produced genetically identical hdAds that differ only in the virion protein components, which are derived from the helper virus. We show that the vectors have identical expression characteristics in vitro, regardless of the serotype, and that the sequential use of hdAd of different serotypes allows for successful repeat vector administration in vivo.
Results
Generation of an Ad2-based helper virus Ad2LC8cCARP contains an Ad5 left-end identical to that of our previous helper virus Ad5LC8cluc including the 'floxed' packaging signal ( Figure 1 ). As such, we expected that the efficiency of Cre-mediated excision of the packaging signal (⌿) would be similar for the two viruses. Preliminary experiments to test for excision in the 293Cre4 cell line showed that ⌿ was indeed excised from Ad2LC8cCARP with an efficiency similar to that observed for Ad5LC8cluc (data not shown). Thus, Ad2LC8cCARP should act as an equally effective helper virus in our Cre/loxP system, resulting in only low levels of helper virus contamination in the resulting vector stocks.
Ad2LC8cCARP encodes all structural proteins derived from Ad2, with the possible exception of pIX. The pIX gene is located immediately adjacent to E1, and encodes a minor virion structural component that has not been shown to be a major target for neutralizing antibody activity, 64, 65 and is highly conserved between type 2 and type 5 Ads (138 of 139 amino acids are identical between Ad2 and Ad5 pIX). Thus, the presence of an Ad5-pIX in our 'Ad2' hdAd vectors should not interfere with their ability to transduce cells in the presence of anti-Ad5 antibodies. We also included a fragment of lambda DNA within the E3 region of Ad2LC8cCARP as a stuffer to prevent RCA formation. If Ad2LC8cCARP were to recombine with the Ad5 sequences contained in the 293 or 293Cre4 cells, it would generate a virus of approximately 39 kb, which greatly exceeds the upper limit for Ad DNA packaging. 66 Consequently, as with our earlier helper Ad5LC8cluc, we have not observed RCA in our helper virus preparations or in stocks of vector produced using Ad2LC8cCARP (data not shown).
Amplification of a hdAd using Ad2LC8cCARP
To determine if Ad2LC8cCARP could amplify hdAd with an efficiency equal to that of Ad5LC8cluc, we transfected duplicate 60-mm dishes of 293Cre cells with 5 g of pRP1050 and, next day, infected the monolayers at a multiplicity of infection (MOI) of 5 with Ad2LC8cCARP. After complete CPE (approximately 72 h), the monolayers were harvested into the medium, freeze-thawed, and an aliquot of the lysates analysed for lacZ-transducing particles. Ad2RP1050 was rescued at a frequency of approximately 400 blue-forming units (b.f.u.) per pmol of transfected DNA, which is similar to the efficiency previously observed for plasmids of comparable size using Ad5LC8cluc, 67 suggesting that Ad2LC8cCARP could indeed act as an effective helper virus in the 293Cre4 cells. We then subjected an aliquot of the crude lysates (500 l) to serial passage on Ad2LC8cCARP-infected 293Cre cells, in order to determine the kinetics of vector amplification. As shown in Figure 2 , Ad2RP1050 was amplified using Ad2LC8cCARP at a rate similar to that previously observed for the Ad5LC8cluc helper virus (RJP and FLG, unpublished results). After four serial passages on the helper virus-infected 293Cre cells, Ad2RP1050 reached a titer of 3.4 × 10 7 b.f.u./ml. A largescale preparation of Ad2RP1050 was performed, yielding 3 × 10 11 b.f.u. from 20 150-mm dishes, with a helper virus contamination of 3.2 × 10 7 p.f.u./ml (approximately 0.01% of the Ad2RP1050 titer). We conclude that Ad2LC8cCARP can act as a helper virus in 293Cre4 cells with an efficiency similar to that of Ad5LC8cluc.
Effect of Ad5 neutralizing antibodies on hdAd2
In theory, an hdAd based on an Ad2 serotype should not be affected by Ad5 neutralizing antibodies, allowing for vector readministration in animals previously treated with an Ad5-based hdAd. To determine if Ad2RP1050 was sensitive to antibodies generated against Ad5, 10 6 b.f.u. of Ad2RP1050, Ad5RP1045 or Ad5CA35 were incubated with serial dilutions of Ad5-neutralizing serum, and then used to infect A549 cells. Twenty-four hours later, crude cell extracts were prepared from the infected cells and assayed for ␤-gal activity. In this assay, infectivity directly correlates with ␤-gal activity and thus neutralizaton of the vector by antibody leads to a corresponding reduction in ␤-gal activity. Both Ad5CA35 and Ad5RP1045 were neutralized by incubation with the Ad5 antibodies, with an almost 100-fold decrease in ␤-gal activity at the highest antibody concentration (Figure 3 ). In contrast, no decrease in ␤-gal activity (or virus infectivity) was noted for Ad2RP1050. These results indicate that, as expected, the virion protein components derived from Ad2LC8cCARP and present in Ad2RP1050 are not sensitive to Ad5 neutralizing antibodies.
In vitro transgene expression Although Ad2RP1050 and Ad5RP1050 are genetically identical, and would be predicted to have virtually identical expression characteristics, the efficiency of cell transduction could be affected by the presence of different virion capsid proteins. It is also possible that subtle differences in the protein coat or core proteins contained within the virion might influence the efficiency of transport of the hdAd DNA to the nucleus or affect promoter activity. We therefore examined transgene expression of Ad2RP1050 and Ad5RP1050 in transduced A549 cells. We chose A549 since E1-deleted first-generation vectors do not undergo productive infection in these cells, and our analysis of transgene expression over time would not be complicated by the presence of small quantities of helper virus. Monolayers of A549 cells in 60-mm dishes were transduced in duplicate with 10 6 b.f.u. of Ad2RP1050 or Ad5RP1050 and, at various times after transduction, crude protein extracts were prepared and analyzed for ␤-gal activity. The hdAd2-and hdAd5-lacZ vectors had virtually identical expression characteristics in vitro over the duration of the experiment (Figure 4) . We conclude that hdAd generated using an Ad2-or Ad5-based helper virus have identical transduction efficiencies and transgene expression characteristics in vitro. 
Generation of neutralizing antibodies in hdAd2-immunized animals
We would predict that animals immunized with a hdAd2 would generate neutralizing antibodies to Ad2, but that these antibodies would have no effect on a hdAd5. We therefore analyzed serum collected at 28 days after injection from mice injected i.v. with 5 × 10 10 particles of Ad2RP1046 for neutralizing antibodies to Ad2 or Ad5. Serum samples were serially diluted and incubated with Ad2RP1050 or Ad5RP1050, and the resulting vector assayed for the ability to transduce A549 cells and express lacZ, as described above. All of the animals immunized with Ad2RP1046 produced neutralizing antibodies to Ad2, which resulted in a 30-to 100-fold decrease in Ad2RP1050 transduction at the highest antibody concentrations examined (Figure 5a ). In contrast, there was no effect on Ad5RP1050, indicating that the hdAd2-immunized animals produced antibodies that were specific to Ad2 (Figure 5b) . Therefore, it appears that helper-dependent Ad vectors based on alternative serotypes have the same general virion characteristics, with respect to presentation of surface antigens, as firstgeneration Ad vectors. Based on these observations, we would predict that use of hdAd based on alternative Ad serotypes should permit vector readministration.
Use of hdAd of alternative serotype allows for repeat vector administration Since mice immunized with the hdAd2 generated antibodies to Ad2, and those antibodies did not cross-react with Ad5, subsequent delivery of hdAd5 to mice preimmunized with hdAd2 should lead to higher levels of transgene expression compared with readministration of hdAd2. Mice were immunized with 10 10 particles of Ad2RP1046 and, 90 days later, injected with 10 8 b.f.u. of either Ad2RP1050 or Ad5RP1050. As a control, naive animals were injected in parallel with the lacZ-expressing vectors. At 3 and 6 days after administration of the lacZ vector, the animals were euthanized and the livers removed and assayed for ␤-gal activity. These experiments generated two notable results. First, the levels of transgene expression in naive animals at days 3 and 6 for both hdAd2 ( r.l.u. per tissue at day 3 for Ad2RP1050 and Ad5RP1050, respectively). These data indicate that hdAds generated using the Ad2 helper virus are able to transduce cells in vivo efficiently, and can lead to high levels of transgene expression, similar to Ad5-based hdAd. Second, administration of a serotype 2 vector into animals immunized (Figure 6a ). In contrast, no decrease in transgene expression compared with naive animals was observed when the re-administered vector was of a different serotype (Figure 6b) . Taken together, these data indicate that the sequential use of hdAd of alternative serotype is an effective strategy for vector readministration.
Discussion
We have previously shown that hdAd can efficiently transduce cells in vitro and in vivo, and can lead to longterm transgene expression with dramatically reduced cellular and inflammatory responses, compared with first-generation Ad vectors. [41] [42] [43] 68 Although the hdAd DNA does persist within nondividing or slowly cycling cells for long periods of time, the episomal nature of Ads (and hdAds) may mean that the vector DNA will eventually be lost from the cell. Thus, although hdAds allow for longer duration transgene expression than observed with first-generation Ads, there may be a requirement for repeat vector administration in order to 'boost' transgene expression levels. The formation of neutralizing antibodies in animals exposed to Ads, which occurs due to the processing and presentation of virion proteins, would reduce the effectiveness of repeat administrations of hdAds, as found with first-generation Ad vectors. Use of alternative Ad serotypes, either of the same 60, 61 or different 46,59 subgroup, allows effective repeat administration of first-generation vectors. We therefore undertook to: (1) construct and characterize a helper virus based on a different serotype than our Ad5-based helper virus; and (2) determine if sequential use of vectors derived from different serotypes could permit efficient hdAd vector readministration.
Considering the overall genetic similarity of Ad2 and Ad5, it is not surprising that an Ad2-based helper virus with a floxed packaging signal was effective in amplifying helper-dependent Ads in the Cre/loxP system ( Figure 2 ). We were able to produce genetically identical hdAds efficiently based on Ad2 or Ad5, and these vectors were equal in their ability to transduce cells and express transgene in vitro and in vivo (Figures 4 and 6) . We would expect that other Ad serotypes with genomes similar to that of Ad5 could also be easily adapted to act as helper virus in the Cre/loxP system. In particular, Ads 1 and 6 belong to the same subgroup (C) as Ads 2 and 5, show high DNA sequence similarity to Ad5, and are relatively well characterized. Consequently, it should be straightforward to develop additional helper viruses based on these two serotypes. However, less well characterized Ad serotypes from other subgroups, or other animal Ads (eg canine Ad) might prove more difficult to utilize as helper viruses. For example, genetic manipulation of other Ads might be hampered by inadequate molecular characterization or lack of an E1 complementing cell line as useful as 293 cells.
Administration of a hdAd based on serotype 2 into animals immunized against Ad2 resulted in a 30-to 100-fold reduction in transgene expression compared with naive animals (Figure 6a ). In contrast, no decrease in transgene expression was observed when the re-administered vector was of a different serotype (Figure 6b ). Taken together, these data indicate that the sequential use of hdAd of alternative serotype is an effective strategy for vector readministration. Interestingly, we did not observe a decrease in expression of lacZ between days 3 and 6 in the hdAd2 (1st)-hdAd5 (2nd) treatment, as has been observed for similar treatments using first-generation Ad vectors. 60 The decrease in expression observed by Mack et al 60 was attributed to cellular immune processes, and this suggests that either hdAd do not elicit such destructive processes or, alternatively, are poor targets.
We have previously shown that use of hdAds can lead to prolonged transgene expression and reduced immune and inflammatory responses compared with first-generation Ad vectors. [41] [42] [43] HdAds retain the other beneficial properties of Ad vectors, including virion stability during vector propagation and purification, and high transduction efficiency of replicating and quiescent cells, while eliminating some of the obstacles and concerns that have been raised with respect to first-and second-generation Ads. We have now shown that, should transgene expression levels decrease over time, the use of hdAds of alternative serotypes will permit readministration of a vector with the identical genotype. It is important to note that, in our experiments, repeat administration was performed with a different reporter gene than was carried by the vector used in the initial animal immunization. Since vector persistence (and hence transgene expression) can be influenced by immune responses to both vector and transgene, 7, 11, 14, 43, 69, 70 the effectiveness of vector readministration using hdAds with different serotypes may ultimately depend primarily on the immunogenicity of the therapeutic gene. The results of this study demonstrate that, in the absence of transgene effects, the sequential use of hdAd of alternative serotype is an effective strategy for vector readministration.
Materials and methods
Cell and virus culture All cell culture media and reagents were obtained from Gibco Laboratories (Grand Island, NY, USA). 293 71 and A549 (human lung carcinoma, ATCC CCL 185) cells were grown in monolayer in F-11 minimum essential medium supplemented with 100 U of penicillin per ml, 100 mg of streptomycin per ml, 2.5 mg fungizone per ml, and 10% fetal bovine serum for cell maintenance or 5% horse serum after virus infection. Recombinant Ad helper viruses were grown and titered on 293 cells, as previously described. 72 The 293-derived cell line that stably expresses the Cre recombinase, 293Cre4, 63 was propagated in complete F-11 medium supplemented with 0.4 mg/ml G418.
Helper-dependent Ad vectors were propagated and titered as previously described. 39 pRP1045 is a hdAd deleted of all Ad protein coding sequences, but containing an Ad5 head-to-tail inverted terminal repeat (ITR) junction and packaging signal, as well as the E. coli ␤-galactosidase gene under the regulation of the murine cytomegalovirus immediate-early promoter (MCMV) and Simian virus 40 polyadenylation (pA) sequence. To maintain the size of the vector above the limit for efficient DNA packaging (approximately 28 kb), 67 pRP1045 also
contains an approximately 22 kb fragment of eukaryotic DNA derived from the human hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene, as described elsewhere, 68 pRP1050 is essentially identical to pRP1045, but is deleted of a 1.2 kb StuI fragment from the HPRT sequence, and has expression characteristics identical to pRP1045 (RJP and FLG, unpublished results). pRP1046 is similar in structure to pRP1050, but contains the human secreted alkaline phosphatase cDNA (hSEAP, Tropix) replacing the lacZ gene. For clarity, hdAd will be designated with the appropriate serotype. For example, Ad5RP1050 and Ad2RP1050 are generated using Ad5LC-8cluc and Ad2LC8cCARP, respectively. For Ad2RP1046, the titer of the vector was determined spectrophometrically, assuming 1A 260 = 1.1 × 10 12 particles.
Construction of a Cre/loxP helper virus based on Ad2
The Ad2-based helper virus, Ad2LC8cCARP was constructed using both molecular cloning and in vivo genetic recombination techniques (Figure 1 ). pLC8c was used to provide the 'left end' of the helper virus (ie left ITR and floxed packaging signal), and has been previously described. 39 Plasmid, pLC8c, was cotransfected into 293 cells with Ad2 genomic DNA digested with PshAI. The resulting viruses were screened by restriction analysis for those which contained the majority of protein coding sequences derived from the Ad2 virus. One virus, designated Ad2LC8c, had resulted from a recombination event to the left of a BspHI site located at 7882 bp on the Ad5 map. Thus, in Ad2LC8c all coding sequences for virion capsid proteins, with the possible exception of pIX, are derived from Ad2.
Because of the requirement for multiple serial passages in order to increase the titer of hdAd, the formation of replication competent adenovirus (RCA) is of concern. Once generated, RCA can rapidly outgrow the vector, leading to highly contaminated vector stocks. We have shown that the inclusion of a 'stuffer' segment within the E3 region, such that recombination between the helper virus and the Ad5 sequences contained in the 293 or 293Cre cells results in a virus which is above the upper packaging limit for Ad virions (approximately 105% of the wild-type genome), 66 can eliminate the potential for RCA. 39 We therefore designed an Ad2-based stuffer plasmid which contained a fragment of lambda DNA located within the E3 region as follows (Figure 1b) . pFG28, which contains the right 40 map units of Ad2 (FLG, unpublished), was digested with PacI and ligated with PacI-digested pCARPABS1, which contains a 5.6 kb fragment of lambda DNA (22346-27972 bp of the conventional lambda map) cloned into the unique BamHI site of pABS1 (Neo r ). 73 The resulting plasmid, pFG28CARP, was partially digested with HpaI, resulting in the loss of the neomycin resistance gene, part of the lambda DNA, and other bacterial sequences derived from pABS1, and recircularized, generating pFG28CARPc. To transfer the stuffer segment to Ad2LC8c, DNA isolated from Ad2LC8c virions was digested with BspHI and cotransfected with pFG28CARPc into 293 cells. The resulting viruses were screened by restriction analysis for those containing the lambda stuffer segment within the E3 region, and one positive isolate, designated Ad2LC8cCARP, was used for subsequent experiments.
Transgene expression studies
Methods for preparation of cell samples and assays for ␤-gal are described elsewhere. 68 For in vivo expression studies, adult female FVB/n mice (Harlan) were injected through the tail vein with the indicated vector dose in a volume of 200 l. For antibody titer determinations, blood samples were removed by orbital bleed, incubated overnight at 4°C, and the serum cleared by two rounds of centrifugation at 16 000 g for 5 min in a microcentrifuge. The serum samples were then stored at −70°C. The method for preparation and analysis of ␤-gal levels in the liver of mice is described elsewhere. 68 Virus neutralization assays The Ad5 neutralizing antibodies used in these experiments were generated in rabbits by injection of a firstgeneration Ad5 vector (M Anton and FL Graham, unpublished) and Ad2 antibodies were made in mice by injecting a serotype 2 hdAd. Aliqouts (10 6 b.f.u. in 100 l) of a first-generation Ad vector (Ad5CA35), 74 Ad5RP1045, AdRP1050 or Ad2RP1050, all containing an identical ␤-gal expression cassette, were incubated with serial dilutions (100 l) of antibody-containing serum. After a 1 h incubation at 37°C, the treated vectors were used to infect 22-mm dishes of A549 cells for 1 h, the monolayers washed twice with PBS, maintenance medium replaced, and the quantity of ␤-gal present within the cells assayed 24 h later. In this assay, the quantity of ␤-gal produced in the cells correlates directly with the efficiency of cell transduction.
